Tuesday, July 28, 2020 10:31:05 AM
2.5|1 forward stock split. Is this something good or not since it seems like you are getting extra shares, same money value, seems strange they would do it at a stock price of only $10
Recent TLSA News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/19/2026 11:00:19 AM
- Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis • GlobeNewswire Inc. • 05/19/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2026 11:00:20 AM
- Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab • GlobeNewswire Inc. • 05/14/2026 11:00:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/01/2026 09:00:43 PM
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2026 09:00:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2026 11:00:16 AM
- Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function • GlobeNewswire Inc. • 04/16/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/14/2026 11:00:12 AM
- Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress • GlobeNewswire Inc. • 04/14/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 11:00:01 AM
- Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging • GlobeNewswire Inc. • 04/01/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 12:00:10 PM
- Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/20/2026 09:10:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/20/2026 04:15:03 PM
- Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab • GlobeNewswire Inc. • 01/20/2026 04:15:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2026 08:12:46 PM
- Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares • GlobeNewswire Inc. • 01/16/2026 07:45:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/16/2026 12:39:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2026 12:00:09 PM
- Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million • GlobeNewswire Inc. • 01/16/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2026 12:00:06 PM
- Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2025 01:00:16 PM
